biperiden has been researched along with Disease Exacerbation in 1 studies
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bittencourt, S | 1 |
| Ferrazoli, E | 1 |
| Valente, MF | 1 |
| Romariz, S | 1 |
| Janisset, NRLL | 1 |
| Macedo, CE | 1 |
| Antonio, BB | 1 |
| Barros, V | 1 |
| Mundim, M | 1 |
| Porcionatto, M | 1 |
| Aarão, MC | 1 |
| Miranda, MF | 1 |
| Rodrigues, AM | 1 |
| de Almeida, AG | 1 |
| Longo, BM | 1 |
| Mello, LE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biperiden for Prevention of Epilepsy in Patients With Traumatic Brain Injury[NCT04945213] | Phase 3 | 312 participants (Anticipated) | Interventional | 2023-01-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for biperiden and Disease Exacerbation
| Article | Year |
|---|---|
Modification of the natural progression of epileptogenesis by means of biperiden in the pilocarpine model of epilepsy.
Topics: Action Potentials; Animals; Autonomic Nervous System; Biperiden; Chronic Disease; Cytokines; Disease | 2017 |